Molecular mechanisms of sglt2 inhibitor on cardiorenal protection

Yi Chou Hou, Cai Mei Zheng, Tzung Hai Yen, Kuo Cheng Lu

研究成果: 雜誌貢獻回顧型文獻同行評審

6 引文 斯高帕斯(Scopus)

摘要

The development of sodium-glucose transporter 2 inhibitor (SGLT2i) broadens the therapeutic strategies in treating diabetes mellitus. By inhibiting sodium and glucose reabsorption from the proximal tubules, the improvement in insulin resistance and natriuresis improved the cardiovascular mortality in diabetes mellitus (DM) patients. It has been known that SGLT2i also provided renoprotection by lowering the intraglomerular hypertension by modulating the pre-and post-glomerular vascular tone. The application of SGLT2i also provided metabolic and hemodynamic benefits in molecular aspects. The recent DAPA-CKD trial and EMPEROR-Reduced trial provided clinical evidence of renal and cardiac protection, even in non-DM patients. Therefore, the aim of the review is to clarify the hemodynamic and metabolic modulation of SGLT2i from the molecular mechanism.
原文英語
文章編號7833
頁(從 - 到)1-25
頁數25
期刊International journal of molecular sciences
21
發行號21
DOIs
出版狀態已發佈 - 十一月 1 2020

ASJC Scopus subject areas

  • 催化
  • 分子生物學
  • 光譜
  • 電腦科學應用
  • 物理與理論化學
  • 有機化學
  • 無機化學

指紋

深入研究「Molecular mechanisms of sglt2 inhibitor on cardiorenal protection」主題。共同形成了獨特的指紋。

引用此